A novel method for screening the glutathione transferase inhibitors
© Wang et al; licensee BioMed Central Ltd. 2009
Received: 07 October 2008
Accepted: 16 March 2009
Published: 16 March 2009
Glutathione transferases (GSTs) belong to the family of Phase II detoxification enzymes. GSTs catalyze the conjugation of glutathione to different endogenous and exogenous electrophilic compounds. Over-expression of GSTs was demonstrated in a number of different human cancer cells. It has been found that the resistance to many anticancer chemotherapeutics is directly correlated with the over-expression of GSTs. Therefore, it appears to be important to find new GST inhibitors to prevent the resistance of cells to anticancer drugs. In order to search for glutathione transferase (GST) inhibitors, a novel method was designed.
Our results showed that two fragments of GST, named F1 peptide (GYW KIKGL V) and F2 peptide (KWR NKK FELGLEFPN L), can significantly inhibit the GST activity. When these two fragments were compared with several known potent GST inhibitors, the order of inhibition efficiency (measured in reactions with 2,4-dinitrochlorobenzene (CDNB) and glutathione as substrates) was determined as follows: tannic acid > cibacron blue > F2 peptide > hematin > F1 peptide > ethacrynic acid. Moreover, the F1 peptide appeared to be a noncompetitive inhibitor of the GST-catalyzed reaction, while the F2 peptide was determined as a competitive inhibitor of this reaction.
It appears that the F2 peptide can be used as a new potent specific GST inhibitor. It is proposed that the novel method, described in this report, might be useful for screening the inhibitors of not only GST but also other enzymes.
Glutathione transferase (GST) (EC 188.8.131.52) is a multifunctional enzyme, which protects cells against cytotoxic and genotoxic stresses. GST catalyzes the conjugation of cytotoxic agents to glutathione (γ-glutamyl-cysteinyl-glycine), producing less reactive chemical species. Changes in GST levels have been found to correlate with resistance to anticancer drugs through accelerated detoxification of these drugs' substrates [1–4].
Members of the GST family are present at relatively high concentrations in the cytosol of various mammalian tissues. Over-expression of GST isozymes has been reported in a number of different human cancers, when compared to the corresponding normal tissues [5, 6]. A 2-fold increase in GST activity was found in lymphocytes from chronic lymphocytic leukemia (CLL) patients, who were resistant to chlorambucil, relative to lymphocytes from untreated CLL patients . As GST isozymes are frequently up-regulated in many solid tumors and lymphomas, inhibition GST activity has become a new drug design concept [8–13]. These facts led to the search for and design of GST inhibitors, including their synthetic analogues and glutathione conjugates, however, most of the existing inhibitors are either too toxic to be used in vivo or are effective only in vitro [14, 15].
Although several different GST inhibitors have been reported, to our knowledge, there are no reports on design of the GST inhibitors according to GST sequence. In this report, a novel, covering all gene fragments (CAGF), cloning method was used to screen the GST fragments which can bind to glutathione and form the inhibitory complexes. These inhibitory complexes act as modified substrate inhibitors or substrate homologues to inhibit the GST activity. The method described in this report should be suitable not only for development of novel drugs inhibiting the GST activity, but also for finding effective inhibitors in other enzyme-catalyzed reaction systems.
Screening the GST inhibitors using the fragments of GST
The binding efficiency of E. coli cells after each round of panning procedure on glutathione Sepharose 4B beads.
E. coli cells
Input E. coli cells
Unbound E. coli cells
Elution efficiency (%)
E. coli cell expressing GST fragments
The binding efficiency of E. coli cells expressing F1 and F2 peptides on glutathione Sepharose 4B beads.
E. coli cells
Input E. coli cells
Unbound E. coli cells
Elution efficiency (%)
E. coli cells expressing F1 peptide
E. coli cells expressing F2 peptide
E. coli cells (control)
The binding of synthesized peptides F1, F2, F3 and F4 to glutathione Sepharose 4B beads.
Results of the screening with the use of the CAGF cloning method are consistent with the crystallographic data. The structure-function analysis has shown that GST contains one important binding site (G-site) for glutathione . Experiments based on kinetic and chemical modification techniques indicated that the active site might contain either His, Cys, Trp, Arg, or Asp [17–21]. The crystal structure indicates that GST binds two molecules of glutathione sulfonate at the G-site. Several groups have investigated changes in amino acids involved in the formation of the G site of GST. The Tyr6, as one of the important components of the G site, is conserved in many mammalian GSTs. Tyr6 plays an essential role in stabilizing the thiolate anion of glutathione through hydrogen bonding. This residue was studied using site-directed mutagenesis, and when Tyr was replaced by different amino acids, GST has lost at least 90% its specific activity [22–24]. Our results with the CAGF cloning method also suggest an important function of Tyr6 in glutathione binding, therefore, the screening results are consistent with the crystallographic data.
The binding characteristics of F1 and F2 peptides
The binding of F1 and F2 peptides to glutathione.
Binding characteristics of peptides on glutathione Sepharose 4B beads
The binding of F1 and F2 peptides to GST.
Peptide-glutathione Sepharose 4B beads
Binding characteristics of GST on peptide-glutathione Sepharose 4B beads
F1 peptide-glutathione Sepharose 4B beads
F2 peptide-glutathione Sepharose 4B beads
The inhibitory effects of selected peptides
Effects of different inhibitors (two selected peptides F1 and F2, tannic acid, cibacron blue, hematin, and ethacrynic) on the GST activity.
Inhibitor (1 μM)
Specific GST activity (units/mg)
CDNB (1 mM)
DCNB (1 mM)
2.80 ± 0.01 (100%)
4.51 ± 0.02 (100%)
1.20 ± 0.01(43.1%)
2.65 ± 0.02 (58.8)
0.73 ± 0.01 (26.1%)
1.49 ± 0.02 (33.2%)
0.16 ± 0.01 (5.6%)
0.49 ± 0.01 (10.9%)
0.51 ± 0.01 (18.3%)
0.96 ± 0.01 (21.3%)
0.99 ± 0.01 (35.2%)
1.90 ± 0.02 (42.1%)
1.54 ± 0.01 (55.1%)
3.66 ± 0.02 (81.2%)
These results indicate that we have found an efficient GST inhibitor, the F2 peptide, which is more efficient than hematin (35.2% activity with CDNB as a substrate, 42.1% activity with DCNB as a substrate). We also found another inhibitor of this reaction, the F1 peptide, which is more efficient than ethacrynic acid (55.1% activity with CDNB as a substrate, 81.2% activity with DCNB as a substrate).
The inhibition characteristics of selected peptides
The characterization of the F1 peptide as an inhibitor of the GST-catalyzed reaction (The Vmax, Ki and [I]/Ki values of the GST-catalyzed reaction in the presence of the F1 inhibit peptide were determined).
F1 peptide concentration [I] (μM)
Vmax value (μmol/mg/min)
Ki value (μM)
The characterization of the F2 peptide as an inhibitor of the GST-catalyzed reaction (The Vmax, Ki and [I]/Ki values of the GST-catalyzed reaction in the presence of the F2 inhibit peptide were determined).
F2 peptide concentration [I] (μM)
Km value (mM)
Ki value (μM)
Moreover, with the changing concentrations of CDNB or DCNB, from 0.5 mM to 2 mM, the kinetics of the GST-catalyzed reaction remained similar in the reaction system containing GST, glutathione and the inhibitor (F1 peptide or F2 peptide). Therefore, we conclude that CDNB and DCNB cannot significantly affect the inhibition efficiency of F1 peptide or F2 peptide.
All these results show that effective non-competitive inhibitor F1 peptide and competitive inhibitor F2 peptide were found by using the CAGF cloning method. Although F1 and F2 peptides comprise only a small part of GST, they show significant inhibition efficiencies in the GST-catalyzed reaction.
The development of resistance to anticancer agents is a primary concern in cancer chemotherapy. In this light, it is obvious that the emergence of drugs, such as the GST inhibitors, able to overcome this resistance is a advancement [10, 11]. Therefore, it is of special interest to develop GST inhibitors able to enhance the therapeutic index of anticancer drugs. Ethacrynic acid and quinine, which are both GST inhibitors, have been reported to reverse the resistance to melphalan and doxorubicin of cancer cell lines with increased GST expression . In fact, ethacrynic acid has been used as an inhibitor of GST in vivo. However, first-generation GST inhibitors (e.g. ethacrynic acid) were unsuccessful in clinical trials. This might be due to its lack of specific function for GST isozyme, and propensity to react with other chemicals. In addition, there caused a number of unwanted clinical side effects. Therefore, more specific GST inhibitors may eliminate some of these undesirable features.
Here, we used the CAGF cloning method to find the GST fragments interacting with glutathione, which might be useful for the finding of GST inhibitors. We found two inhibitory peptide fragments, F1 peptide and F2 peptide. Our results revealed that F2 peptide is a potent inhibitor of the reaction with IC50 of 0.6 μM (Fig. 3).
On the other hand, the F2 peptide is located in the marginal position of the G site of GST (Fig. 6B). It may be easy for F2-glutathione complex to duck into the catalytic site of GST. We assume that the F2-glutathione complex may be docked into the G site of GST. Thus, F2-glutathione may directly interfere with the catalytic site of GST and glutathione. Since the F2-glutathione causes a competitive inhibition, the F2 peptide may be a good candidate for further studies on cancer chemomodulation.
The following mechanism was used to explain the inhibitory activity of GST fragment-substrate complexes on GST-catalyzed reaction. When the F1 or F2 peptide bound to the substrate glutathione, a peptide-glutathione complex was formed. Although GST can convert glutathione into the reaction products, this enzyme cannot convert the peptide-glutathione inhibitor into the product. Thus, the binding of the peptide-glutathione to GST can inactive the enzyme activity. We speculate that peptide-glutathione occupied the functional domain or affected the functional domain of GST. Thus, GST-peptide-glutathione or GST-glutathione-peptide complex cannot catalyze the conversion of glutathione (Fig 4B and 4C). Here, the function of peptide-glutathione inhibitor is just like the substrate homologue or substrate-modifying inhibitor .
In summary, we have determined two glutathione-binding fragments of the GST sequence, and found that the F2 peptide, selected by the CAGF cloning method, can be considered as the inhibitor of GST. The F2 peptide is a potent inhibitor, stronger than hematin and ethacrynic acid, but weaker than tannic acid and cibacron blue. We suggest that the F2 peptide can be considered in applications against GST-induced multidrug resistance.
In conclusion, we have successfully found a F2 peptide as GST inhibitor with the novel screening method from GST sequence. Our screening method should be useful for screening many different enzyme inhibitors.
Generation of the GST library
The forward primer FP1: 5' ATG TCC CCT ATA CTA GGT 3' and reverse primer RP1: 5' TCA CGA TGC GGC CGC TCG 3' were used to amplify the Schistosoma japonicum full-length GST gene  from the pGEX4T-2 plasmid DNA vector (Amersham). The amplified DNA fragments were purified with the QIAquick PCR purification kit (QIAGEN). The following reaction system was used: 1 ng pGEX4T-2 plasmid, 50 mM Tris-HCl (pH 7.8), 5 mM MgCl2, 10 mM 2-mercaptoethanol, 10 μg/ml BSA, 1 ng forward primer FP1 and 1 ng reverse primer RP1, 20 μM dNTP, 1 μM dideoxynucleotides (ddNTP), 2 units DNA Polymerase I (Invitrogen), and ddH2O to the reaction volume of 100 μl; incubation at 15°C for 30 to 60 min.
The amplified DNA library was purified by using the phenol-chloroform method, and dissolved in water. The DNA library was digested with the Exonuclease VII (Epicentre), which has a high enzymatic specificity for single-stranded DNA and exhibits both 5' → 3' and 3' → 5' exonuclease activities. This enzyme is especially useful for rapid removal of single-stranded oligonucleotide primers.
Cloning the GST library into pFliTrx vector
The cloning of DNA library into the pFliTrx vector (Invitrogen) was performed as shown in Fig. 1. The pFliTrx was amplified using Pfx DNA polymerase (Invitrogen) with the forward primer FP2: 5' GGT CCG TCG AAA ATG ATC GCC CCG ATT CTG GAT 3' and the reverse primer RP2: 5' CGG ACC GCA CCA CTC TGC CCA GAA ATC GAC GAA 3'. The two-step PCR reaction was performed under the following conditions: 92°C for 2 min; then 35 cycles at 68°C for 5 min, and 92°C for 30 s. The amplified PCR product was purified by using the QIAquick PCR purification kit (QIAGEN).
The purified PCR product of linearized pFliTrx (without the fusion junction) was used to link it to the DNA library with T4 ligase. The ligation products were introduced into the E. coli GI826 (F-, lacIq, ampC::Ptrp::c I, ΔfliC, ΔmotB, eda::Tn 10) (Invitrogen).
Screening the GST fragments which can bind to glutathione
The GST library was introduced to E. coli GI826 competent cells, which were then cultured in 50 ml of IMC medium (1 × M9 salts, 0.2% casamino acid, 0.5% glucose, 1 mM MgCl2) containing 100 μg/ml ampicillin with shaking (225–250 rpm) to saturation (OD600 = 3) for 15 hours at 25°C. E. coli cells were added to 50 ml IMC medium containing 100 μg/ml ampicillin and 100 μg/ml tryptophan for induction. The cells were grown at 25°C with shaking for 6 hours. Then, 1 ml of glutathione Sepharose 4B (Amersham) slurry and 1 ml of tryptophan-induced culture broth were added to 40 ml of the PBS buffer in a 50 ml tube, and kept at the room temperature for 30 min, centrifuged at 1,000 × g for 10 min at the room temperature, then resuspended in the PBS buffer, and centrifuged at 1,000 × g for three more times. Finally, the pellet was resuspended in 2 ml of PBS, and 500 μl of elution buffer (50 mM Tris-HCl, 10 mM reduced glutathione, pH 8.0) were added to elute the bound E. coli cells. The eluted E. coli cells were used for the next panning procedure. Following the panning procedure, 100 μl of the eluted solution was added on the RMG plates (1 × M9 salt, 0.2% casamino acid, 0.5% glucose, 1 mM MgCl2, 1.5% agar). The plates contained 100 μg/ml ampicillin for selection of the positive clones. Then the single positive clones from the RMG plates were picked up, and 150 single clones were used for screening the GST inhibitors.
Screening of GST fragments which can inhibit the GST activity
150 single positive clones (grown on the RGB plates), that could tightly bind to the glutathione Sepharose 4B, were picked up from the plates, and cultured separately in 50 ml of IMC medium containing 100 μg/ml ampicillin for 15 hours at 25°C, then induced with 100 μg/ml tryptophan for 6 hours. E. coli cells were washed with the PBS buffer for three times at 4°C, and suspended in the 5 ml PBS solution, respectively.
Recombinant S. japonicum GST, glutathione, tannic acid, cibacron blue, hematin, ethacrynic acid, 1,2-dichloro-4-nitrobenzene (DCNB) and 2,4-dinitrochlorobenzene (CDNB) were purchased from Sigma-Aldrich, and used to measure the GST activity.
To measure the GST activity, glutathione and CDNB solutions were added (to final concentration of 1 mM) to 100 μl of E. coli cell suspension (108 cells). Then, GST solution was added (the cell suspension without glutathione was used as the control). The GST activity was measured by using the spectrophotometric assay .
The single clones, which can produce the GST inhibitory peptide, were selected again, and the plasmid DNA was extracted for determination of inserted sequences. The whole screening procedures were performed five times. Finally, plasmid DNAs were extracted from E. coli cells expressing inhibitory peptides, and sequenced.
Analysis of the binding of peptides to glutathione
The binding characteristics of selected peptides to glutathione were determined according to the analysis of binding of synthesized peptides to the glutathione Sepharose 4B beads. The amount of glutathione in the glutathione Sepharose 4B beads was estimated according to the assumption (according to the manufacturere's information) that there are about 200–400 μmol glutathione/g dried beads. An average value of 300 μmol glutathione/g dried beads was used to calculate the amount of glutathione in the glutathione Sepharose 4B beads. In our experiments, appropriate amount of wet glutathione Sepharose 4B beads (equal to 1 mg dry beads) was added to a 1.5 ml Eppendorf tube, and different amounts of synthesized peptides were added into the tube. After binding for 10 min at 37°C, the binding complexes were separated by centrifugation (12,000 × g for 10 min) and concentrations of bound and free peptides were determined by using the Lowry method . Scatchard analysis was used to determine the Kd and Bmax values. Bmax means the maximum binding sites of synthesized peptide on glutathione Speharose 4B beads (μmol peptide/μmol glutathione). Kd is a dissociation constant (pM). Thus, a low Kd value indicates a high affinity.
Analysis of the binding of peptide-glutathione complex to GST
The binding of selected peptide-glutathione complexes with GST were determined on the basis of analysis of binding of GST to the peptide-glutathione Sepharose 4B bead complex. Wet glutathione Sepharose 4B beads (equal to 1 mg dry wet) was added into a 1.5 ml Eppendorf tube for binding to peptides. After the binding of peptides to glutathione Sepharose 4B beads at 37°C for 10 min, the unbound peptides were washed out. Then, different amounts of GST were added into the tube. After binding for 10 min at 37°C and separation of the bound complexes by centrifugation, the amounts of bound and free GST were determined by the Lowry method . Scatchard analysis was used to determine the Kd and Bmax values. Bmax means the maximum binding site of GST with the peptide on peptide-glutathione Speharose 4B beads (μmol GST/μmol peptide-glutathione). Kd is a disassociation constant (pM).
Enzyme inhibition assay
When the screening experiments were performed, four peptides were synthesized to analyze their inhibition efficiencies. F1 peptide (GYW KIKGL V, yield: 25.3 mg), F2 peptide (KWR NKK FELGLEFPN L, yield: 28.1 mg), F3 peptide (GKIKGV, yield: 2.2 mg) and F4 peptide (KWNKFELGLEFPL, yield: 1.9 mg) were obtained from the Invitrogen (Custom Peptide Synthesis, with the purity > 95%). Recombinant S. japonicum GST (~40 units/mg), glutathione, tannic acid, cibacron blue, hematin, ethacrynic acid, 1,2-dichloro-4-nitrobenzene (DCNB) and 2,4-dinitrochlorobenzene (CDNB) were from Sigma-Aldrich Co. The inhibition studies were carried out according to the previously described method  at 25°C using glutathione (1 mM) and CDNB (1 mM) or DCNB (1 mM) as substrates. The inhibitors (tannic acid, cibacron blue, hematin, ethacrynic acid or the synthesized peptides) were added to the reaction mixture and GST activity was determined.
The peptide concentration resulting in 50% inhibition (IC50) was determined from a plot of remaining activity versus peptide concentration. Protein concentration was measured according to the Lowry method . Enzyme inhibitory kinetic studies were carried out using various concentrations of glutathione and CDNB and different concentrations of synthetic peptides (0.8, 1.6, 3.2 μM).
covering all gene fragments
chronic lymphocytic leukemia.
This work was supported by National Natural Science Foundation of China (Grant number: 30400077), University of Gdańsk (task grant no. DS/1480-4-114-09) and Institute of Biochemistry and Biophysics of the Polish Academy of Sciences (task grant 32.1).
- Mannervik B, Danielson UH: Glutathione transferases-structure and catalytic activity. CRC Crit Rev Biochem. 1988, 23: 283-337.View ArticleGoogle Scholar
- Pickett CB, Lu AY: Glutathione S-transferases: gene structure, regulation, and biological function. Annu Rev Biochem. 1989, 58: 743-764.View ArticleGoogle Scholar
- Coles B, Ketterer B: The role of glutathione and glutathione transferases in chemical carcinogenesis. Crit Rev Biochem Mol Biol. 1990, 25: 47-70.View ArticleGoogle Scholar
- Douglas KT: Mechanism of action of glutathione-dependent enzymes. Adv Enzymol Relat Areas Mol Biol. 1987, 59: 103-167.Google Scholar
- Adang AE, Brussee J, Gen van der A, Mulder GJ: The glutathione-binding site in glutathione S-transferases. Investigation of the cysteinyl, glycyl and gamma-glutamyl domains. Biochem J. 1990, 269: 47-54.View ArticleGoogle Scholar
- Abramovitz M, Homma H, Ishigaki S, Tansey F, Cammer W, Listowsky I: Characterization and localization of glutathione-S-transferases in rat brain and binding of hormones, neurotransmitters, and drugs. J Neurochem. 1988, 50: 50-57.View ArticleGoogle Scholar
- Schisselbauer JC, Silber R, Papadopoulos E, Abrams K, LaCreta FP, Tew KD: Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients. Cancer Res. 1990, 50: 3562-3568.Google Scholar
- Wilce MC, Parker MW: Structure and function of glutathione S-transferases. Biochim Biophys Acta. 1994, 1205: 1-18.View ArticleGoogle Scholar
- Wilce MC, Feil SC, Board PG, Parker MW: Crystallization and preliminary X-ray diffraction studies of a glutathione S-transferase from the Australian sheep blowfly, Lucilia cuprina. J Mol Biol. 1994, 236: 1407-1409.View ArticleGoogle Scholar
- Hayes JD, Pulford DJ: The glutathione S-transferase supergene family: regulation of GST and the contribution of the isozymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995, 30: 445-600.View ArticleGoogle Scholar
- Tidefelt U, Elmhorn-Rosenborg A, Paul C, Hao XY, Mannervik B, Eriksson LC: Expression of glutathione transferase p as a predictor for treatment results at differentstages of acute nonlymphoblastic leukemia. Cancer Res. 1992, 52: 3281-3285.Google Scholar
- Black SM, Beggs JD, Hayes JD, Bartoszek A, Muramatsu M, Sakai M, Wolf CR: Expression of human glutathione S-transferases in Saccharomyces cerevisiae confers resistance to the anticancer drugs adriamycin andglutachlorambucil. Biochem J. 1990, 268: 309-315.View ArticleGoogle Scholar
- Dirven HAAM, van Ommen B, van Bladeren PJ: Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res. 1994, 54: 6215-6220.Google Scholar
- Hayeshi R, Chinyanga F, Chengedza S, Mukanganyama S: Inhibition of human glutathione transferases by multidrug resistance chemomodulators in vitro. J Enzyme Inhib Med Chem. 2006, 21: 581-587.View ArticleGoogle Scholar
- Muleya V, Hayeshi R, Ranson H, Abegaz B, Bezabih MT, Robert M, Ngadjui BT, Ngandeu F, Mukanganyama S: Modulation of Anopheles gambiae Epsilon glutathione transferase activity by plant natural products in vitro. J Enzyme Inhib Med Chem. 2008, 23: 391-399.View ArticleGoogle Scholar
- Kursula I, Heape AM, Kursula P: Crystal structure of non-fused glutathione S-transferase from Schistosoma japonicum in complex with glutathione. Protein Pept Lett. 2005, 12: 709-712.View ArticleGoogle Scholar
- Ricci G, Del Boccio G, Pennelli A, Lo Bello M, Petruzzelli R, Caccuri AM, Barra D, Federici G: Redox forms of human placenta glutathione transferase. J Biol Chem. 1991, 266: 21409-21415.Google Scholar
- van Ommen B, den Besten C, Rutten AL, Ploemen JH, Vos RM, Muller F, van Bladeren PJ: Active site-directed irreversible inhibition of glutathione S-transferases by the glutathione conjugate of tetrachloro-1,4-benzoquinone. J Biol Chem. 1988, 263: 12939-12942.Google Scholar
- Awasthi YC, Bhatnagar A, Singh SV: Evidence for the involvement of histidine at the active site of glutathione S-transferase psi from human liver. Biochem Biophys Res Commun. 1987, 143: 965-970.View ArticleGoogle Scholar
- Tamai K, Satoh K, Tsuchida S, Hatayama I, Maki T, Sato K: Specific inactivation of glutathione S-transferases in class Pi by SH-modifiers. Biochem Biophys Res Commun. 1990, 167: 331-338.View ArticleGoogle Scholar
- Chang LH, Wang LY, Tam MF: The single cysteine residue on an alpha family chick liver glutathione S-transferase CL 3-3 is not functionally important. Biochem Biophys Res Commun. 1991, 180: 323-328.View ArticleGoogle Scholar
- Manoharan TH, Gulick AM, Puchalski RB, Servais AL, Fahl WE: Structural studies on human glutathione S-transferase pi. Substitution mutations to determine amino acids necessary for binding glutathione. J Biol Chem. 1992, 267: 18940-18945.Google Scholar
- Wang RW, Newton DJ, Huskey SE, McKeever BM, Pickett CB, Lu AY: Site-directed mutagenesis of glutathione S-transferase YaYa. Important roles of tyrosine 9 and aspartic acid 101 in catalysis. J Biol Chem. 1992, 267: 19866-19871.Google Scholar
- Kolm RH, Sroga GE, Mannervik B: Participation of the phenolic hydroxyl group of Tyr-8 in the catalytic mechanism of human glutathione transferase P1-1. Biochem J. 1992, 285: 537-540.View ArticleGoogle Scholar
- Hansson J, Berhane K, Castro VM, Jungnelius U, Mannervik B, Ringborg U: Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor ethacrynic acid. Cancer Res. 1991, 51: 94-98.Google Scholar
- Burg D, Mulder GJ: Glutathione conjugates and their synthetic derivatives as inhibitors of glutathione-dependent enzymes involved in cancer and drug resistance. Drug Metab Rev. 2002, 34: 821-863.View ArticleGoogle Scholar
- Smith DB, Johnson KS: Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene. 1988, 67: 31-40.View ArticleGoogle Scholar
- Habig WH, Pabst MJ, Jakoby WB: Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974, 249: 7130-7139.Google Scholar
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem. 1951, 193: 265-275.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.